CLUSTER filed Aug 11, 2026 at 17:15 ET
Three Dianthus Therapeutics insiders (CEO, General Counsel, and a Director) sold a total of ~$3.2M in open-market shares over a 3-day window, with the CEO alone selling ~$15.6M including option exercises. The sales are large in absolute terms but represent only ~0.05% of the $6.3B market cap, falling below the 0.1% materiality threshold. The CEO's sales coincide with option exercises at $8.44, suggesting tax-planning or diversification rather than a bearish signal, consistent with the weak predictive power of insider sales clusters per academic literature.